Novartis has reported that the Phase III CANOPY-2 study of canakinumab (ACZ885) in combination with the chemotherapy agent docetaxel failed to meet the primary endpoint of overall survival (OS) in patients with advanced or metastatic non-small cell lung cancer (NSCLC).
A human monoclonal antibody, canakinumab is an interleukin-1beta (IL-1β) inhibitor of pro-tumour inflammation (PTI) in NSCLC.
Go deeper with GlobalData
The trial enrolled 237 adult subjects with locally advanced or metastatic NSCLC whose disease progressed while on or after previous platinum-based chemotherapy and PD-(L)1 inhibitor immunotherapy.
It analysed the role of canakinumab plus docetaxel in second- or third-line therapy as compared with docetaxel alone in NSCLC.
Part I of the trial was a previously reported safety run-in study to analyse appropriate dosage while Part 2 assessed OS.
Novartis chief medical officer and Global Drug Development head John Tsai said: “While results from the CANOPY-2 trial are not what we hoped for in patients with advanced or metastatic non-small cell lung cancer who have been treated with other lines of therapy, these data give us valuable insights into IL-1β inhibition.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalData“Ongoing Phase III studies in non-small cell lung cancer continue, evaluating canakinumab in earlier treatment settings.”
The company expects to report final results from a Phase III CANOPY-1 study analysing canakinumab as first-line therapy for locally advanced or metastatic NSCLC plus pembrolizumab (immunotherapy) and platinum-based doublet chemotherapy before the year-end.
Another Phase III CANOPY-A study is assessing canakinumab in the adjuvant setting after surgical resection and cisplatin-based chemotherapy for preventing cancer relapse. It has so far enrolled over 950 subjects and is anticipated to enrol a total of 1,500 participants.
Accounting for approximately 85% of lung cancer diagnoses, NSCLC results in nearly 1.7 million new cases every year. At present, the five-year survival rate is less than 20% for lung cancer, which lowers further when detected at later stages.
